An important point is that, although the underlying mechanisms of its induction await to be resolved, MCT4 is suggested to be a biomarker and a therapeutic target of pathogenic ND mutation-harbouring metastatic tumours. This evidence concerns the gene SLC16A3 and metastatic neoplasm.